ArticleImmunogenetics2009
sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease.
Article in Immunogenetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.Current obesity reports · 2025Review
- Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease.Frontiers in physiology · 2025Review
- Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer.The Libyan journal of medicine · 2019Article
- Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease.Journal of clinical and experimental hepatology · 2018Review
- Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice.Scientific reports · 2017Article
- A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression.Cancer medicine · 2016Article
- Genetic and epigenetic mechanisms of NASH.Hepatology international · 2016Review
- Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene Polymorphisms and Hepatitis B Virus Infection.Jundishapur journal of microbiology · 2015Article
- Genetic background in nonalcoholic fatty liver disease: A comprehensive review.World journal of gastroenterology · 2015Review
- Tumor necrosis factor-related apoptosis inducing ligand gene polymorphisms are correlated with gastric cancer in central China.Pharmaceutical research · 2015Article
- Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia.PloS one · 2015Article
- Association between TRAIL gene polymorphisms and the susceptibility and severity of lumbar disc degeneration.International journal of clinical and experimental pathology · 2015Article
- Genetic polymorphisms and haplotypes of TRAIL gene correlate with NSCLC susceptibility in a group of Chinese patients.International journal of clinical and experimental medicine · 2015Article
- Regulation of the human TRAIL gene.Cancer biology & therapy · 2012Review
- Genetic variants in candidate genes influencing NAFLD progression.Journal of molecular medicine (Berlin, Germany) · 2012Review
- Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.Expert review of gastroenterology & hepatology · 2011Review
- Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer?Archives of medical science : AMS · 2010Article
- TNF superfamily gene polymorphism as prognostic factor in early breast cancer.Journal of cancer research and clinical oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily, and has been identified as a novel mediator of fatty liver disease (FLD). The aim of our study was to further investigate the relationship between TRAIL and FLD. We found that soluble TRAIL (sTRAIL) concentrations in non-alcoholic FLD (NAFLD) patients were significantly higher than those of controls, and that sTRAIL levels positively correlated with triglyceride concentrations in NAFLD patients. Our results also indicated that the AA/TT genotypes of TRAIL at 1525/1595 engendered a lower risk of FLD attack and a less severe form of steatosis for NAFLD patients in Chinese population. This study provides a means to test for susceptibility to FLD and may assist in the diagnosis of FLD. In addition, we found that 1525G/A and 1595C/T sites were in complete linkage disequilibrium in Chinese population. This might indicate a haplotype with high genetic frequency of TRAIL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.